Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants

2.2K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.2K
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

1.5K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.5K
Stimulants01:29

Stimulants

1.2K
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
1.2K
Cholinergic Receptors: Nicotinic01:15

Cholinergic Receptors: Nicotinic

6.4K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
6.4K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.8K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.8K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

926
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
926

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age (juvenile to aged) and sex effects on in vitro CYP2A6 enzyme activity in African green monkeys using nicotine and coumarin.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Faster CYP2A6 increases COPD and lung cancer risk by increasing smoking quantity: a mediated mendelian randomization and observational mediation study.

Respiratory research·2026
Same author

PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

In Vitro Drug-Drug Interactions between Oxycodone and Commonly Co-Consumed Drugs in Rat and Human Liver Microsomes.

Current drug metabolism·2026
Same author

Tau-PET imaging and blood biomarkers reveal early tauopathy in special operations forces exposed to repetitive blast.

Brain communications·2026
Same author

Alpha-methyl-para-tyrosine and amphetamine ameliorate hyperactivity in a novel mouse model of dopamine transporter deficiency syndrome.

EMBO molecular medicine·2026

Related Experiment Video

Updated: Mar 20, 2026

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
08:47

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration

Published on: February 10, 2012

14.0K

Brain CYP2B induction can decrease nicotine levels in the brain.

Kristine L P Garcia1,2, Anh Dzung Lê1,2, Rachel F Tyndale1,2

  • 1Departments of Pharmacology and Toxicology and Psychiatry, Toronto, Ontario, Canada.

Addiction Biology
|May 28, 2016
PubMed
Summary
This summary is machine-generated.

Chronic nicotine exposure increases brain CYP2B enzyme activity, reducing nicotine levels in the brain. This finding in rats suggests a mechanism that may influence smoking behavior and withdrawal symptoms in humans.

Keywords:
CYP2Bbrainmetabolismmicrodialysisnicotinerat

More Related Videos

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
09:25

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

11.9K
A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol
09:30

A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol

Published on: January 18, 2018

9.0K

Related Experiment Videos

Last Updated: Mar 20, 2026

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
08:47

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration

Published on: February 10, 2012

14.0K
Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
09:25

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

11.9K
A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol
09:30

A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol

Published on: January 18, 2018

9.0K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Nicotine is metabolized by the enzyme CYP2B.
  • Brain CYP2B levels are elevated in nicotine-treated animals and human smokers.
  • Previous studies showed nicotine treatment alters CYP2B expression and substrate response in the brain.

Purpose of the Study:

  • To investigate the in vivo effect of CYP2B induction on brain nicotine levels following chronic nicotine administration.
  • To determine if changes in brain CYP2B activity influence the pharmacokinetics of nicotine in the brain.

Main Methods:

  • Utilized in vivo brain microdialysis in rats to measure brain nicotine concentrations.
  • Administered nicotine subcutaneously and assessed levels on day 1 and after 7 days of treatment.
  • Investigated the role of CYP2B by using a specific inhibitor (C8-xanthate) and a washout period.

Main Results:

  • Seven-day nicotine treatment significantly reduced peak brain nicotine levels post-injection, consistent with CYP2B induction.
  • Brain nicotine levels returned to baseline after a two-week washout period.
  • Inhibition of brain CYP2B activity increased nicotine levels, confirming the enzyme's role in nicotine metabolism.

Conclusions:

  • Chronic nicotine exposure induces brain CYP2B activity, leading to decreased brain nicotine levels.
  • This mechanism may modulate nicotine's reinforcing effects and contribute to smoking behavior and withdrawal symptoms.
  • Elevated brain CYP2B in smokers could potentially lower brain nicotine concentrations, impacting addiction and cessation efforts.